Advertisement
UK markets close in 5 hours 54 minutes
  • FTSE 100

    7,957.09
    +25.11 (+0.32%)
     
  • FTSE 250

    19,807.84
    -2.82 (-0.01%)
     
  • AIM

    742.19
    +0.08 (+0.01%)
     
  • GBP/EUR

    1.1692
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2616
    -0.0022 (-0.17%)
     
  • Bitcoin GBP

    55,818.59
    +235.64 (+0.42%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.95
    +0.60 (+0.74%)
     
  • GOLD FUTURES

    2,226.10
    +13.40 (+0.61%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,488.07
    +10.98 (+0.06%)
     
  • CAC 40

    8,245.17
    +40.36 (+0.49%)
     

Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Eragny-sur-Oise, France, January 12th, 2021 - 18h00 CEST – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets.

Under the contract, the liquidity account had the following holdings as of December 31st, 2020:

  • 584 shares

  • -35,87 euros

During the first half of 2020, the following have been negotiated:


PURCHASE

4,582 shares

1,803.84 euros

513 transactions

SALE

5,010 shares

1,947.17 euros

503 transactions


For the prior period (June 30th, 2020), the corresponding figures were:

ADVERTISEMENT
  • 1 012 shares

  • 364,57 euros

As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:

  • 74 738 shares

  • 7 561,33 euros

Following the acquisition of Louis Capital Market|Midcap Partners by the group TPICAP Plc, the liquidity contract previously owned by Louis Capital Markets UK, LLP has been automatically transferred on 31/12/2020 to TP ICAP (EUROPE), the French entity of the group TPICAP, authorized and regulated by the French Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

The detail of day-to-day activities is as follows:

Purchase

Sale

ALSAF FP

Trading volume

Number of shares

Cash (EUR)

Trading volume

Number of shares

Cash (EUR)

Total

513

4 582

1 803,84

503

5 010

1 947,17

20200701

4

59

29,32

1

1

0,50

20200702

3

38

18,60

6

101

51,73

20200703

5

75

36,77

5

60

31,07

20200706

1

1

0,52

9

158

82,22

20200707

4

71

35,64

5

62

32,71

20200708

4

57

28,40

2

21

10,75

20200709

4

56

27,30

1

1

0,49

20200710

5

65

30,90

1

1

0,48

20200713

2

14

6,45

5

71

33,60

20200714

3

35

16,15

4

56

26,75

20200715

4

55

25,63

1

1

0,48

20200716

2

15

6,90

4

56

26,41

20200717

1

1

0,48

5

67

32,33

20200720

5

75

35,28

2

12

5,82

20200721

3

38

18,30

1

1

0,49

20200722

1

1

0,49

6

119

59,14

20200723

5

58

28,61

2

21

10,67

20200724

4

32

15,39

1

1

0,49

20200727

3

22

10,49

11

202

105,98

20200728

4

51

24,87

5

57

28,71

20200729

4

51

24,84

2

2

1,00

20200730

4

46

22,17

4

50

24,93

20200731

4

39

18,42

1

1

0,47

20200803

3

24

11,50

2

21

10,29

20200804

4

18

8,48

4

56

27,10

20200805

5

22

10,26

2

21

10,11

20200806

2

4

1,88

2

221

103,02

20200807

4

25

11,59

2

19

9,01

20200810

5

21

9,67

3

30

14,25

20200811

1

1

0,69

11

145

100,76

20200812

8

57

28,86

2

15

7,95

20200813

7

48

22,87

1

1

0,49

20200814

5

32

14,45

6

78

36,63

20200817

5

37

17,21

2

16

7,65

20200818

4

24

10,95

3

21

9,87

20200819

4

24

10,78

2

9

4,14

20200820

6

41

17,55

1

1

0,45

20200821

4

22

9,22

1

1

0,43

20200824

1

1

0,43

4

44

18,81

20200825

2

5

2,07

2

14

5,88

20200826

3

19

7,84

3

22

9,30

20200827

4

24

9,88

3

22

9,35

20200828

2

10

4,09

4

41

17,23

20200831

4

27

11,03

2

9

3,76

20200901

6

46

17,69

1

1

0,39

20200902

4

23

8,62

1

1

0,38

20200903

1

1

0,38

4

44

16,77

20200904

1

1

0,38

3

22

8,35

20200907

5

38

13,90

5

56

21,47

20200908

3

23

8,61

6

67

26,80

20200909

5

45

16,75

4

36

14,04

20200910

3

26

9,47

6

60

22,71

20200911

4

35

13,11

1

1

0,38

20200914

4

32

11,85

4

36

13,86

20200915

4

32

11,84

1

1

0,37

20200916

1

1

0,37

4

39

14,56

20200917

3

27

10,04

1

1

0,37

20200918

3

21

7,78

1

1

0,38

20200921

4

30

10,94

4

40

15,20

20200922

3

25

8,88

4

39

14,39

20200923

4

32

11,52

3

20

7,39

20200924

4

32

11,37

4

39

14,31

20200925

4

34

11,90

2

8

2,87

20200928

2

9

3,18

6

72

26,55

20200929

4

36

12,65

5

48

18,14

20200930

3

25

8,97

2

10

3,69

20201001

1

1

0,35

2

10

3,55

20201002

6

63

21,69

1

1

0,35

20201005

5

50

16,52

11

125

45,09

20201006

10

92

37,69

5

50

22,08

20201007

3

25

9,55

6

71

28,12

20201008

5

52

20,68

1

1

0,40

20201009

11

100

35,72

1

1

0,36

20201012

7

53

18,56

1

1

0,36

20201013

1

1

0,35

3

31

10,80

20201014

1

1

0,34

1

1

0,34

20201015

4

29

9,77

1

1

0,34

20201016

2

10

3,36

1

1

0,34

20201019

2

10

3,34

3

32

10,89

20201020

6

42

13,84

1

1

0,33

20201021

5

33

10,38

4

53

17,23

20201022

5

37

11,35

1

1

0,32

20201023

7

45

13,31

2

4

1,23

20201026

11

62

17,45

4

54

16,54

20201027

9

49

12,47

2

21

5,66

20201028

10

58

13,41

1

1

0,24

20201029

7

35

7,37

2

21

4,60

20201030

5

25

5,13

10

161

35,23

20201102

1

1

0,23

9

134

30,66

20201103

2

15

3,47

7

90

21,59

20201104

4

47

11,26

5

53

13,10

20201105

10

119

27,56

4

41

10,20

20201106

1

1

0,25

11

135

33,90

20201109

5

66

16,25

4

33

8,59

20201110

5

62

15,00

2

12

3,00

20201111

3

29

6,97

2

15

3,69

20201112

2

19

4,57

4

39

9,64

20201113

2

20

4,83

2

15

3,69

20201116

1

1

0,25

9

94

24,39

20201117

3

32

8,28

5

37

10,01

20201118

6

77

19,84

2

11

2,96

20201119

3

30

7,55

1

1

0,25

20201120

4

43

10,59

4

38

9,75

20201123

1

1

0,26

4

39

10,14

20201124

2

20

5,03

3

30

7,74

20201125

3

32

7,97

3

30

7,72

20201126

3

27

6,72

4

41

10,57

20201127

1

1

0,25

4

33

8,39

20201130

2

21

5,29

2

13

3,34

20201201

1

1

0,26

11

101

27,90

20201202

1

1

0,29

4

25

7,13

20201203

4

53

14,42

5

29

8,67

20201204

3

34

9,24

2

10

2,80

20201207

4

51

13,61

4

27

7,54

20201208

4

55

14,82

4

31

8,62

20201209

5

66

17,37

1

1

0,27

20201210

5

65

16,94

3

24

6,46

20201211

1

1

0,27

1

1

0,27

20201214

1

1

0,27

7

81

21,61

20201215

4

52

13,61

11

103

28,68

20201216

4

58

15,18

9

77

21,66

20201217

1

1

0,28

11

85

24,37

20201218

5

81

22,10

6

40

11,43

20201221

4

58

15,33

11

77

21,63

20201222

1

1

0,35

11

63

22,21

20201223

1

1

0,90

11

44

39,60

20201224

11

74

75,07

6

11

12,20

20201225

0

0

0,00

0

0

0,00

20201228

0

0

0,00

0

0

0,00

20201229

10

136

89,82

0

0

0,00

20201230

9

119

63,52

11

31

18,72

20201231

10

121

81,71

1

1

0,69

Next financial release:

Annual 2020 results, January 14th, 2021 (post-market)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal fractures treatments. The company develops and manufactures kits combining sterile implants and single-use instruments, available at any time for the surgeon. These technologies enable minimally invasive approach, reducing the risk of cross contamination and infection, in the interest of the patient with a positive impact on hospitalization durations and costs. Protected by 17 patent families, the SteriSpineTM PS are CE marked and FDA approved. Safe Orthopaedics has its headquarters close to Paris (95610 Eragny-sur-Oise - France) has subsidiaries in the UK, Germany, United States and in the Lyon area where the manufacturing company is located. The Group employs around 150 employees.

For more information : www.SafeOrthopaedics.com



Contacts

Safe Orthopaedics
François-Henri Reynaud
Chief Financial Officer
Tél. : +33 (0)1 34 21 50 00
investors@safeorthopaedics.com

Press Relations
Ulysse Communication
Pierre-Louis Germain / +33 (0)6 64 79 97 61 / plgermain@ulysse-communication.com
Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com

Attachment